Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

... tel AVIV, Israel, July 14 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (TASE: EMIT, Nasdaq: EMITF ), announced today that, its subsidiary (in which EI h...

Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy

... tel AVIV, Israel, June 17 /PRNewswire/ -- A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generati...

Clinical Trial Results of Pollogen's TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology

... tel AVIV, Israel, June 2 /PRNewswire/ -- Clinical trial results using the regen(TM) system, the newest aesthetic solution powered by 3rd generation TriPol...

InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients

... tel AVIV, Israel, May 6 /PRNewswire/ -- InspireMD, developers of MGuard(TM), an...pire-md.com Contact: Jonina Ohayon Marketing Director tel +972-52-5791120 jonina@inspire-md.com ...

Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding

... chomsy@c3bs.com Mayra Beydoun, Brand & Communication Manager tel : +32-10-39-41-00 mbeydoun@c3bs.com http://www.c3bs.com Citigate Dewe Rogerson Chris Gardner/Heather Keohane/Nina Enegren tel : +44(0)207-638-9571 chris.gardner@citigatedr.co.uk ...

MGuard(TM) Coronary Stent System Approved in Israel

... tel AVIV, Israel, December 8 /PRNewswire/ -- InspireMD, Ltd. announced that the...pire-md.com Contact: Jonina Ohayon Marketing Director tel +972-52-5791120 jonina@inspire-md.com ...

Lytix Presents LTX-109 Anti-Microbial Data at ICAAC

...es: Anders Fugelli Head of Business Development Lytix Biopharma AS P.O. Box 6447, Tromso Research Park N-9294 Tromso, Norway tel +47-924-81-432 Email: anders.fugelli@lytixbiopharma.com ...

Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test

...sen, Managing Director DiaGenic ASA, Grenseveien 92, NO-0663 Oslo, Norway tel +47-95939918 Email: erik.christensen@diagenic.com Media Inquiries For Applied Biosystems: Renaldo Juanso Applied Biosystems tel +1-650-638-5354 Email: renaldo.juanso@appliedbiosystems.com ...

Critical Pharmaceuticals Enter Sustained Release hGH Arena

...w.criticalpharmaceuticals.com Corporate Inquiries Gareth King, Chief Business Officer Critical Pharmaceuticals, BioCity Nottingham NG1 1GF UK tel +44-115-8820100; +44-7720-051988 Email: gareth.king@criticalpharmaceuticals.com ...

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin

... please contact: ThromboGenics Patrik De Haes, CEO tel : +32-16-75-13-10 patrik.dehaes@thrombogenics.com Desire Collen, Chairman tel : +32-16-75-13-10 desire.collen...

New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients

...nity in pediatric liver-transplant patients post-transplantation. Working in a cooperative group involving several institutions in Petach- Tikva and tel Aviv in Israel, Israeli and his colleagues focused on the use of the Cylex ImmuKnow assay to monitor cell-mediated immunity post-transplant in pediatr...

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds

...al Cancer Centre Singapore Carol Ang Carol.Ang.S.Y@nccs.com.sg Tel: +65 62369424 National University Hospital Lisa Ang lisa_ang@nuh.com.sg tel :(65) 6772 5117 Manchester Cancer Research Centre Alicia Custis Alicia.Custis@christie.nhs.uk Reference List 1) ...

Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics

... maintaining the highest principles of excellence and compassion toward patients and their families. Affiliated with the Sackler School of Medicine at tel Aviv University, Rabin Medical Center is recognized for superior healthcare in all domains of medicine and is devoted to pursuing cutting edge researc...

PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated

...or Director of Public Relations PAREXEL International Tel: +781-434-4409 Email: Jennifer.Baird@PAREXEL.com Rebecca Passo SHIFT Communications tel : +617-681-1817 Email : rpasso@shiftcomm.com ...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...ients by the time of diagnosis that there are few effective therapies available," said investigator Dr. Bella Kaufman, The Chaim Sheba Medical Center, tel Hashomer, Israel. "We are very excited to see these results as they provide the promise of future options for these patients." Available online Fo...

BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials

... BARC South Africa, Dr. Jessica Trusler, Medical Director tel +27 11 358 07 47 BARC USA, Mr. Scott Keddy, Sr. Director Bus... Tel: +1 516 719 1052 BARC Europe, Dr. Guy Dewil, COO tel + 329 329 2 327 BARC is an independent global central laboratory, with sub...

Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents

... Provides the Optimal Combination of Scaffolding, Deliverability and Conformability tel AVIV, Israel, May 12 /PRNewswire/ -- Medinol is proud to announce that it has received CE Mark for its Presillion(TM) CoCr Coronary Stent, enabling ph...

GlaxoSmithKline Reports Further Progress of Oncology Portfolio

...inflammatory breast cancer (IBC): final results of the expanded HER2+ cohort in EGF103009 [Phase II]Dr. Bella Kaufman, The Chaim Sheba Medical Center, tel Hashomer, Israel, abstract # 636, poster presentation, Monday, June 02, 2008, 2 pm - 6 pm, S-Hall A1 Melanoma Phase II trial of elesclomol* (f...

ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)

...er Tel.: +1-212-201-0920 steve.pakola@thrombogenics.com Patrik De Haes, COO tel : +32-16-34-61-94 patrik.dehaes@thrombogenics.com Citigate Dewe Rogerson Sylvie Berrebi/Amber Bieleck...

Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid

...ial Dynamics President and CEO tel +1 212 850 5683 tel +61 3 9605 5900 Mary McSwiggan Phosphagenics Limited Investor Relations Manager tel +61 3 9605 5907 ...

InterCure Announces 100,000th RESPeRATE Unit Sold

...ignificant and lasting reduction of blood pressure within weeks. About InterCure, Ltd. InterCure, a medical device company, publicly traded on the tel Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathin...

PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri

..., Director of Public Relations PAREXEL International Tel: +781-434-4409 Email: Jennifer.Baird@PAREXEL.com Rebecca Passo SHIFT Communications tel : +617-779-1817 Email : rpasso@shiftcomm.com ...

AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study

... more information contact: AspenBio Pharma, Inc. Gregory Pusey, Chairman tel 303-722-4008 Investor Relations: Liolios Group, Inc. Scott Liolios or Ron Both tel 949-574-3860 ...

BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality

...of Biotech and Biomedical Engineering at Ben-Gurion University. About BioLineRx BioLineRx, a clinical stage drug development company traded on the tel Aviv Stock Exchange (BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's current produc...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

...ore information visit PipelineReview.com. SOURCE: La Merie Business Intelligence Jorge Márquez C/Casp 33 B 4º 2ª. 08010 Barcelona tel + 34 93 342 91 97 Fax + 93 342 91 98 eMail: jorge.marquez@lamerie.com Online Store:

Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer

...t and CEO, tel. +46 46 19 20 49 Tomas Leanderson, Chief Scientific Officer, tel +46 46 19 20 95 Cecilia Hofvander, Manager Corporate Communication, tel. +4...Active Biotech AB (org.nr 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden tel +46 46-19 20 00 Fax +46 46-19 20 50 ...

Active Biotech's I-3D Micro-dosing Clinical Trial Concluded

...-3D project is being conducted in cooperation with Chelsea Therapeutics. Active Biotech AB (org.nr 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden tel +46 46-19 20 00 Fax +46 46-19 20 50 ...

Seroquel Sustained Release Schizophrenia Data Presented at ECP Congress in Madrid

...: +44 (0) 207 304 5084 Jonathan Hunt, Tel: +44 (0) 207 304 5087 Karl Hard, Tel: +44 (0)207 304 5322 Ed Seage, Tel: +1 302 886 4065 Jorgen Winroth, tel + 1 212 579 0506 ...

Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting

... Investor Relations 1202 Geneva Tel:+41 22 414 36 00 Tel:+41 22 414 36 01 Switzerland Media Relations, USA Investor Relations, USA www.merckserono.net tel :+1 781 681 23 40 Tel:+1 781 681 25 52 News Release Parkinson’s disease, Alzheimer’s disease, other cognitive disorders and Restless Leg...

NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan

...nager of Corporate Relations and Market Analysis - tel +33 (0) 4 97 24 53 42 - tel (direct): (+45) 4442 4765 tel (direct): (+1) 609 919 7937